Title:
PHARMACEUTICAL COMPOSITION COMPRISING MIXED ANTIBODIES ANTI-CTLA4 AND ANTI-PD1 AND THERAPEUTIC USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/160517
Kind Code:
A1
Abstract:
The present disclosure relates to the use of a pharmaceutical composition comprising mixed antibodies anti-CTLA4 and anti-PD1 in combination with lenvatinib to treat kidney cancer.
Inventors:
YANG XIN'AI (CN)
ZHANG YINGMIN (CN)
WANG PEIZHEN (CN)
XU AIFENG (CN)
ZHANG YINGMIN (CN)
WANG PEIZHEN (CN)
XU AIFENG (CN)
Application Number:
PCT/CN2023/077316
Publication Date:
August 31, 2023
Filing Date:
February 21, 2023
Export Citation:
Assignee:
QILU PHARMACEUTICAL CO LTD (CN)
International Classes:
A61P35/00; A61K39/395; A61P35/04; C07K16/28; C07K16/30
Domestic Patent References:
| WO2017205014A1 | 2017-11-30 | |||
| WO2021178657A1 | 2021-09-10 | |||
| WO2021143799A1 | 2021-07-22 | |||
| WO2021219138A1 | 2021-11-04 |
Foreign References:
| CN110312523A | 2019-10-08 | |||
| US20190276542A1 | 2019-09-12 | |||
| CN110404066A | 2019-11-05 |
Download PDF:
Previous Patent: MESSAGE PROCESSING METHOD AND RELATED DEVICE
Next Patent: ANAPRAZOLE SODIUM ENTERIC-COATED TABLET AND PREPARATION METHOD THEREFOR
Next Patent: ANAPRAZOLE SODIUM ENTERIC-COATED TABLET AND PREPARATION METHOD THEREFOR